Characteristics and quality of life of people living with comorbid disorders in substance use recovery residences

被引:0
|
作者
Obekpa, Elizabeth O. [1 ]
Mccurdy, Sheryl A. [2 ]
Gallardo, Kathryn R. [2 ]
Rodriguez, Serena A. [2 ]
Cazaban, Cecilia Ganduglia [3 ]
Brown, H. Shelton [4 ]
Yang, James J. [5 ]
Wilkerson, J. Michael [2 ]
机构
[1] UTHlth Houston, Inst Implementat Sci, Sch Publ Hlth, Houston, TX 77030 USA
[2] UTHlth Houston, Dept Hlth Promot & Behav Sci, Sch Publ Hlth, Houston, TX USA
[3] UTHlth Houston, Dept Management Policy & Community Hlth, Sch Publ Hlth, Houston, TX USA
[4] Univ Texas Sch Publ Hlth, Dept Management Policy & Community Hlth, Austin, TX USA
[5] UTHlth Houston, Dept Biostat & Data Sci, Sch Publ Hlth, Houston, TX USA
关键词
health-related quality of life; EQ-5D-5L; comorbidity; opioid use disorder; medication for opioid use disorder; recovery residences; integrated care; recovery housing; PRIMARY MEDICAL-CARE; OPIOID-USE DISORDER; HEALTH; ABUSE; ALCOHOL; INDIVIDUALS; DEPENDENCE; ADDICTION; MORTALITY; IMPACT;
D O I
10.3389/fpubh.2024.1412934
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Opioid use disorder (OUD) is associated with significant morbidity and mortality; however, research on physical and mental health comorbidities and health-related quality of life (HRQoL) among people taking medication for OUD (MOUD) and living in recovery residences is sparse. We investigated the prevalence of comorbidities and examined which EQ-5D-5L HRQoL dimensions are most affected by these comorbidities.Methods Data were collected from 358 residents living in 14 Texas-based recovery residences from April 2021 to June 2023. The EQ-5D-5L descriptive system comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has five levels of perceived problems, dichotomized into "No problems" (level 1) and "Any problems" (levels 2-5) for analyses. Cross-sectional analyses of residents' characteristics, comorbidities (categorized as mental health disorders or association with major body systems), and EQ-5D-5L dimensions were conducted using Chi-squared or Student t-tests. Multivariable logistic regression models were used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs).Results The mean [SD] age of residents was 36.0 [8.9]. Most residents were non-Hispanic White (68.7%), male (59.7%), unemployed (66.3%), and engaged in polysubstance use (75.4%). The most frequently reported comorbidities were mental health (26.5%), respiratory (26.3%), neurological (19.3%), cardiovascular (18.2%), and musculoskeletal (17.0%) disorders. The most reported HRQoL problems were anxiety/depression (75.8%) and pain/discomfort (53.2%). In the unadjusted regression models, all comorbidities, except mental health (negative association) and digestive (no association) disorders, were positively associated with HRQoL problems. The usual activities dimension was the most affected by comorbidities, followed by mobility and pain/discomfort. Increasing age was positively associated with cardiovascular disorders (aOR = 1.06; 95% CI = 1.03-1.10), musculoskeletal disorders (aOR = 1.03; 95% CI = 1.00-1.06), mobility problems (aOR = 1.05; 95% CI = 1.01-1.09), and pain/discomfort problems (aOR = 1.02; 95% CI = 1.00-1.05). Illicit drug use was positively associated with mobility problems (aOR = 3.36; 95% CI = 1.20-9.45). Neurological (aOR = 2.71; 95% CI = 1.38-5.33) and musculoskeletal (aOR = 2.57; 95% CI = 1.25-5.29) disorders were positively associated with pain/discomfort problems. MOUD duration was negatively associated with mental health disorders (aOR = 0.14; 95% CI = 0.08-0.22) but not HRQoL.Conclusions Comorbidities significantly predict HRQoL among individuals with OUD. Our findings highlight the need for an integrated care model to treat OUD and comorbidities to sustain recovery and improve health and HRQoL.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Pharmacotherapy of comorbid mood, anxiety, and substance use disorders
    Brady, KT
    Verduin, ML
    SUBSTANCE USE & MISUSE, 2005, 40 (13-14) : 2021 - 2041
  • [32] Morbidity and mortality in schizophrenia with comorbid substance use disorders
    Lahteenvuo, Markku
    Batalla, Albert
    Luykx, Jurjen J.
    Mittendorfer-Rutz, Ellenor
    Tanskanen, Antti
    Tiihonen, Jari
    Taipale, Heidi
    ACTA PSYCHIATRICA SCANDINAVICA, 2021, 144 (01) : 42 - 49
  • [33] Assessment and Treatment of Mood Disorders and Comorbid Substance Use
    Gold, Alexandra K.
    PSYCHIATRIC ANNALS, 2024, 54 (09)
  • [34] Integrated treatment of comorbid depression and substance use disorders
    Charney, DA
    Paraherakis, AM
    Gill, KJ
    JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (09) : 672 - 677
  • [35] Management of comorbid bipolar disorder and substance use disorders
    Salloum, Ihsan M.
    Brown, Edson Sherwood
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2017, 43 (04): : 366 - 376
  • [36] Current Challenges With Comorbid Psychiatric and Substance Use Disorders
    Crockford, David
    CANADIAN JOURNAL OF ADDICTION, 2021, 12 (03) : 4 - 6
  • [37] Treatment of Comorbid Substance Use Disorders and ADHD in Youth
    Carrellas N.
    Wilens T.E.
    Anselmo R.
    Current Treatment Options in Psychiatry, 2016, 3 (1) : 15 - 27
  • [38] Management of the Adolescent with Substance Use Disorders and Comorbid Psychopathology
    Bukstein, Oscar G.
    Horner, Michelle S.
    CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA, 2010, 19 (03) : 609 - +
  • [39] Prevalence of comorbid pathological gambling in substance use disorders
    Cargonja, P.
    Jonovska, S.
    Jengic, V. Sendula
    Sugnet, T.
    EUROPEAN PSYCHIATRY, 2023, 66 : S565 - S566
  • [40] Epidemiology of comorbid substance use and psychiatric disorders in Asia
    Thirthalli, Jagadisha
    Kumar, Channaveerachari Naveen
    Arunachal, Gautham
    CURRENT OPINION IN PSYCHIATRY, 2012, 25 (03) : 172 - 180